Evogene (EVGN) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Evogene (NASDAQ:EVGN) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04), MarketWatch Earnings reports. Evogene had a negative return on equity of 33.97% and a negative net margin of 1,147.40%. The business had revenue of $0.64 million during the quarter.

EVGN traded down $0.05 during trading hours on Thursday, reaching $1.95. 2,514 shares of the stock traded hands, compared to its average volume of 1,770. Evogene has a fifty-two week low of $1.98 and a fifty-two week high of $4.11.

Separately, ValuEngine lowered shares of Evogene from a “buy” rating to a “hold” rating in a report on Friday, December 21st.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVGN. Jane Street Group LLC acquired a new stake in Evogene during the 4th quarter valued at $71,000. ARK Investment Management LLC grew its holdings in Evogene by 45.0% during the 3rd quarter. ARK Investment Management LLC now owns 242,570 shares of the biotechnology company’s stock valued at $754,000 after purchasing an additional 75,223 shares in the last quarter. Vanguard Group Inc grew its holdings in Evogene by 11.0% during the 3rd quarter. Vanguard Group Inc now owns 514,089 shares of the biotechnology company’s stock valued at $1,599,000 after purchasing an additional 50,823 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Evogene by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 514,089 shares of the biotechnology company’s stock valued at $1,599,000 after purchasing an additional 50,823 shares in the last quarter. 35.37% of the stock is owned by institutional investors and hedge funds.

WARNING: “Evogene (EVGN) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2019/03/14/evogene-evgn-posts-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

About Evogene

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.

Recommended Story: How to calculate the annual rate of depreciation

Earnings History for Evogene (NASDAQ:EVGN)

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply